Sana leapfrogs Moderna for biggest pure-play biotech IPO yet: Data Byte

With Sana’s underwriters exercising their option to buy more shares in its IPO, the company has closed the offering at $675.6 million, leapfrogging Moderna’s 2018 offering to become the largest yet by a pure-play biotech.

Cell therapy company Sana Biotechnology Inc. (NASDAQ:SANA) said late Monday that the banks had exercised their greenshoe option, purchasing another 3.5 million shares on top of the 23.5 million already sold at the $25 offering price...